ALL

New research on patient outcomes presented at the 65th Annual Meeting of the American Society of Hematology

ASH2023: New research on patient outcomes presented
#bigdataforbloodcancer, ALL, AML
November 23, 2023

Researchers validate novel risk profile for childhood ALL using ...
ALL
October 25, 2023

HARMONY Acute Lymphoblastic Leukemia (ALL) abstract presented at EHA2023

HARMONY Acute Lymphoblastic Leukemia (ALL) abstract presented ...
ALL
June 09, 2023

New HARMONY Delphi Survey for #ALL Core Outcome Set open

New HARMONY Delphi Survey for #ALL Core Outcome Set open
ALL, Delphi
January 13, 2022

ALL: Delphi Survey Project: Towards a Core Outcome Set for Acute Lymphoblastic Leukemia (ALL)

ALL, Delphi, HARMONY, Leukemia
July 23, 2021

ALL-5: Exploring the prognostic significance of minimal residual disease (MRD) in children with ALL

ALL-5: Exploring the prognostic significance of minimal residual ...
ALL, HARMONY, Leukemia, Pediatric
October 01, 2020

ALL-4: Harnessing the Power of Big Data to Predict Outcomes Post-Stem Cell Transplant in Adult R/R ALL

ALL-4: Harnessing the Power of Big Data to Predict Outcomes
ALL, HARMONY, Leukemia
October 01, 2020

ALL-3: Exploring treatment patterns and outcomes in older adult B-ALL

ALL-3: Exploring treatment patterns and outcomes in older adult ...
ALL, HARMONY, Leukemia
October 01, 2020

ALL 2: Prognostic Value of IKZF1 Gene Alternations in Adult BCP ALL

Alterations in the IKZF1 gene (deletions and point mutations) ...
ALL, HARMONY, Leukemia
May 28, 2020

The HARMONY Alliance uses big data technologies to
ALL, AML, CLL, MDS, MM, NHL
April 09, 2019

Blood cancers, or hematologic cancers, account for about
ALL, AML, CLL, MDS, MM, NHL
April 09, 2019

ALL 1: Use of Big Data to improve outcomes for patients with Acute Lymphoblastic Leukemia

Use of Big Data to improve outcomes for patients with Acute
ALL, HARMONY, Leukemia
March 15, 2019

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

HARMONY Coordination Office

Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain

harmonyoffice@ibsal.es

HARMONY Communications

European Hematology Association (EHA)
The Hague, The Netherlands

communications@harmony-alliance.eu